Background-Conclusive data about cardiovascular toxicity of nonsteroidal anti-inflammatory drugs (NSAIDs) are sparse.
S elective inhibition of the cyclooxygenase (cox)-2 isoenzyme has been associated with an increase in adverse cardiovascular events, which resulted in the removal of rofecoxib from the market. 1, 2 In contrast, inhibition of cox-1 by aspirin has been associated with a reduction in adverse cardiovascular events. [3] [4] [5] Nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit cox-1 and cox-2 to varying degrees. 6 Some studies have demonstrated that nonselective NSAIDs increase the hazard for adverse cardiovascular outcomes, [7] [8] [9] [10] [11] whereas others have documented a reduced frequency of adverse cardiovascular events. 7, [11] [12] [13] [14] The Safety of Non-Steroidal Anti-Inflammatory Drug Project recently concluded that important knowledge gaps exist, particularly with the traditional NSAIDs. 15 Although the overall association of NSAIDs and cardiovascular risk remains uncertain, even less information is known about the potential cardiovascular toxicity of NSAIDs among women. 16, 17 In the United States, all nonselective NSAIDs carry a black box warning about possible cardiovascular toxicity (fatal/nonfatal myocardial infarction and fatal/ nonfatal stroke), especially among those with existing cardiovascular disease, 18 whereas the European Medicines Agency concluded that a small increased risk of cardiovascular toxicity cannot be excluded. 19 Existing reports have not studied a suitable number of women to determine the potential cardiovascular effects of NSAIDs in women. Accordingly, our first objective was to evaluate the association between regular NSAID use and adverse cardiovascular outcomes among a large cohort of postmenopausal women. We hypothesized that regular NSAID use is associated with an increased risk of adverse cardiovascular outcomes. Our second objective was to evaluate whether the association between regular NSAID use and adverse cardiovascular events is different for the preparations that differ by relative cox-2 and cox-1 inhibition. We hypothesized that agents with relatively more cox-2 than cox-1 inhibition would be associated with an increased hazard for adverse cardiovascular outcomes.
Methods

Study Cohort
The Women's Health Initiative (WHI) study enrolled postmenopausal women aged 50 to 79 years from 40 clinical centers across the United States into ≥1 randomized clinical trials (n=68 132) or an observational study (n=93 676). 20 Enrollment was from October 1, 1993 to December 31, 1998. All participants signed consent forms for participation, which were approved by the institutional review boards of collaborating institutions. The combined cohort of all participants (n=161 808) was selected for these analyses.
Exposure Assessment
Medication use was obtained from direct examination of prescription and nonprescription pill bottles that participants brought to clinic visits. 21 Medication generic/trade names were converted into National Drug Codes from the Master Drug DataBase (Medi-Span, Indianapolis, IN). Regular medication use was defined as at least twice per week for the last 2 weeks. The medication inventory was collected at baseline and updated at years 1, 3, 6, and 9 for randomized trial participants and at year 3 for observational study participants.
Any nonaspirin NSAID use was considered as a single group, including selective cox-2 inhibitors and any of the nonselective NSAIDs. In addition, NSAIDs were then classified according to 3 groups based on their relative selectivity of the cox-2 when compared with cox-1 isoenzyme. Group 1 included the selective cox-2 inhibitors (rofecoxib and celecoxib). Group 2 included nonselective NSAIDs with relatively more cox-2 than cox-1 inhibition (naproxen, nabumetone, diclofenac, etodolac, piroxicam, sulidac, salsalate, ketorolac, and nonaspirin salicylates), and group 3 included nonselective NSAIDs with relatively more cox-1 than cox-2 inhibition (ibuprofen, oxaprozin, ketoprofen, indomethacin, flurbiprofen, tolmetin, and fenoprofen). 22 The above subgroups and analyses were preplanned. In addition, we estimated a Cox regression that classified medication usage by type of medication, plus one group for concurrent usage of several NSAIDs.
Outcome Assessment
Cardiovascular outcomes were ascertained by self-administered medical history updates, which were conducted semiannually for randomized trial participants and annually for observational study participants. 23 Participants who were lost to follow-up (eg, from a disabling disease) or suspected to be dead were matched to the National Death Index to confirm occurrence and cause of death. 23 Trained physician adjudicators reviewed medical records and death certificates to identify outcomes. Nonfatal MI was defined as a chest pain syndrome with characteristic electrocardiographic changes or enzymatic evidence of myocardial damage (elevated creatine kinase-MB or troponin values). Nonfatal stroke was defined as a rapid onset of a neurological deficit attributable to an obstruction or rupture of an arterial vessel which lasted ≥24 hours or a compatible lesion was documented on an imaging study (computed tomography or MRI). All participants were followed up for outcomes from enrollment until 2005. A subsample of 115 400 women (71.3% of the initial cohort) consented to participate in WHI extension I and was followed up for events from 2005 to 2010.
Potential Confounders and Effect Modifiers
All models were adjusted for time-varying usage of aspirin, acetaminophen, and statin medications, as well as baseline demographic information (age, ethnicity, education, income, region of residence within the United States, body mass index, systolic blood pressure, physical activity level, menopausal hormone use, and smoking status) and comorbidities (hypertension, hypercholesterolemia, diabetes mellitus, myocardial infarction, stroke or transient ischemic attack, congestive heart failure, coronary artery bypass grafting or percutaneous coronary intervention, peripheral arterial disease, and rheumatoid arthritis). Baseline reported history of stomach or duodenal ulcer, bleeding problem, osteoarthritis, and cancer were considered as well but found not to be statistically significantly associated with the primary outcome and were not included in the final models.
We conducted subgroup analyses based on 2 perceived levels of risk for cardiovascular events: those with a history of myocardial infarction, cerebrovascular accident/transient ischemic attack, congestive heart failure, diabetes mellitus, or previous coronary artery bypass grafting/percutaneous coronary intervention, and those without any such history. Because the high-risk patients were also likely to be aspirin users, we separately examined a subgroup with no baseline or subsequent use of aspirin and a subgroup with baseline use of aspirin and subsequent use of aspirin (time-varying).
All our cox-regression models use stratification into 6 strata, 1 each for the 4 hormone therapy arms (estrogen alone active treatment and placebo; estrogen-progestin active treatment and placebo; combined n=27 241), 1 for the dietary modification (n=40 654), and 1 for the observational cohort participants (n=92 906). The 2 hormone therapy trials (estrogen alone and estrogen-progestin) had different enrollment criteria (hysterectomy/intact uterus) 24, 25 ; therefore, we wanted to distinguish between those 2 cohorts. In addition, both hormone
WHAT IS KNOWN
• Nonsteroidal anti-inflammatory drugs have been associated with adverse cardiovascular events. • This risk has most consistently been associated with selective cox-2 inhibitors. • Risk of adverse cardiovascular events among nonselective nonsteroidal anti-inflammatory drugs is not as well know, especially among women.
WHAT THE STUDY ADDS
• We confirmed an association of adverse cardiovascular events with selective cox-2 inhibitors among postmenopausal women. • Among the nonselective nonsteroidal anti-inflammatory drugs, naproxen, but not ibuprofen, was associated with adverse cardiovascular events.
therapy trials were stopped early for risk, but at different times, and we therefore found it advisable to control for treatment and control arm in each respective hormone therapy trial. Participants for the calcium-vitamin D trial were recruited from hormone therapy and dietary modification participants during the course of those clinical trials, and we did not use this information for additional stratification. In case a woman was enrolled in both a hormone therapy and the dietary modification trial, she was assigned to the appropriate hormone therapy arm for our stratification.
Statistical Analysis
We used Cox regression (PROC PHREG, SAS software version 9.3; SAS Institute, Inc, Cary, NC) where the primary outcome/dependent variable was the time to the first occurrence of cardiovascular mortality, nonfatal myocardial infarction, or nonfatal stroke, using 6 strata as detailed in the potential confounders and effect modifiers section above, thus allowing for different baseline hazard function for each of the difference cohorts. This association was reported as hazard ratio (HR) and 95% confidence interval (CI). We also individually investigated time to cardiovascular mortality, nonfatal myocardial infarction, nonfatal stroke, congestive heart failure, and all-cause mortality.
If the respective specific outcome was not reported for a participant, that woman was censored at the time of death from any cause or at the point in time of the last documented contact. Confounding was controlled by including statistically significant covariates and interaction terms as suggested by a cutoff value of 0.05 for the respective marginal P values together with the model fit criteria Akaike information criterion and Schwarz criterion. We assessed colinearity and overfitting by observing changes in parameter estimate and their associated CIs for the remaining covariates when including/excluding individual covariates.
Results
Of the 161 808 women enrolled in WHI, 160 801 (99.4%) were available for analysis ( Figure 1 ). At baseline, the 31 433 NSAID users were more likely to be white, overweight or obese, and with higher blood pressure (Table 1) . Complete variables and the number of missing values for each variable are available in Table I in the Data Supplement. Other differences among NSAID users were a higher prevalence of diabetes mellitus, peripheral arterial disease, and rheumatoid arthritis. The 160 801 participants contributed a total of 1 793 222 person-years to this study (mean follow-up of 11.2 years). Of this total time, 53 142 women reported regular NSAID use during ≥1 visit (baseline and postbaseline visits), of which 39 613 women also reported at least some time without regular NSAID usage. Table 2 summarizes the use of specific types of NSAID at baseline and during follow-up. Of 12 720 women reporting the use of a group 2 NSAID at baseline, 14% report later use of a group 1 NSAID, 13% use of a group 3 NSAID, and 52% report no later NSAID use. Likewise, of the 19 817 women reporting the use of a group 3 NSAID at baseline, 10% later report the use of a group 1 NSAID, 13% use of a group 2 NSAID, and 60% report no later NSAID use. Some women reported concurrent use of NSAIDs from ≥1 group (at baseline, 1104 women reported NSAID use from both groups 2 and 3). The primary outcome (cardiovascular mortality, nonfatal myocardial infarction, or nonfatal stroke) was observed in 12 733 cases with an overall incidence rate of 71 events per 10 000 person-years. The unadjusted HR associated with any type of NSAID usage was 1.16 (95% CI, 1.11-1.21; P<0.001), and the adjusted HR was 1.10 (95% CI, 1.06-1.15; P<0.001; Table 3 ). We re-estimated our Cox model for the primary outcome based on the subset of women enrolled in one of the clinical trials (with more frequent medication updates); HR for any NSAID usage was 1.11 (95% CI, 1.04-1.18). Likewise, when we censored all women 3 years after their last medication update, we estimated the HR for any NSAID usage as 1.11 (95% CI, 1.05-1.18).
We replaced usage of any NSAID in the above model by 3 time-varying indicators signifying the usage according to our predefined NSAID groups (Figure 2 , which also shows results for secondary outcomes). Among the selective cox-2 inhibitors, HR was 1.13 (95% CI, 1.04-1.23; P=0.004), nonselective agents with cox-2>cox-1 inhibition group, HR was 1.17 (95% CI, 1.10-1.24; P<0.001), and nonselective agents with cox-1>cox-2 inhibition, HR was 1.01 (95% CI, 0.95-1.07; P=0.884). In addition, we estimated HRs associated with specific NSAID type (time-varying), as detailed in Table 3 . Celecoxib-only HR was 1.13 (1.01-1.27), P=0.031; naproxen-only HR was 1.22 (1.12-1.34), P<0.001; and the ibuprofen-only HR was 1.00 (0.93-1.07), P=0.996.
The group with a history of myocardial infarction, cerebrovascular accident/transient ischemic attack, congestive heart failure, diabetes mellitus, or previous coronary artery bypass grafting/percutaneous coronary intervention experienced 3241 events and did not show an increased hazard with regular NSAID usage (HR, 1.00; 95% CI, 0.92-1.09; P=0.961). However, the group without any of these previous diagnoses and conditions experienced 9312 events and maintained a statistically significantly increased hazard with regular NSAID usage (HR, 1.14; 95% CI, 1.08-1.20; P<0.001).
Among aspirin users who also took NSAIDs, we observed the following associations with NSAID use: group 1 agents (HR, 0.90; 95% CI, 0.76-1.07; P=0.22), group 2 agents (HR, 1.17; 95% CI, 1.04-1.31; P=0.008), and group 3 agents (HR, 0.97; 95% CI, 0.87-1.08; P=0.58). Among nonaspirin users, we observed the following associations with NSAID use: group 1 agents (HR, 1.24; 95% CI, 1.12-1.36; P<0.0001), group 2 agents (HR, 1.18; 95% CI, 1.10-1.27; P<0.0010), and group 3 agents (HR, 1.02; 95% CI, 0.95-1.10; P=0.59).
Discussion
In a large cohort of postmenopausal women, regular NSAID use was associated with a modestly increased hazard for cardiovascular mortality, nonfatal myocardial infarction, or nonfatal stroke. Such an increased risk was observed among selective cox-2 inhibitors (eg, rofecoxib and celecoxib) and nonselective NSAIDs with relatively more cox-2 than cox-1 inhibition (eg, naproxen). Nonselective NSAIDs with relatively more cox-1 than cox-2 inhibition (eg, ibuprofen) were not associated with increased risk. Although the hazard for the primary outcome among nonselective NSAIDs with relatively more cox-2 than cox-1 inhibition was slightly larger than the hazard for cox-2 selective agents, we interpret the magnitude of risk with these 2 classes of agents to be similar. However, cox-2 selective agents seemed to be associated with a greater hazard for stroke, whereas nonselective NSAIDs with relatively more cox-2 than cox-1 inhibition were associated with a greater hazard for myocardial infarction. The risk for cardiovascular mortality and all-cause mortality was marginally increased only among agents with relatively more cox-2 than cox-1 inhibition.
Subgroup analysis was performed according to aspirin use. The results largely mirrored the main study findings, except for concomitant users of selective cox-2 inhibitors. Among aspirin users, concomitant selective cox-2 inhibitors were no longer associated with increased hazard for cardiovascular events although they were still associated with increased hazard for cardiovascular events among nonaspirin users. This observation is consistent with the findings from a platelet function study, which found that rofecoxib did not affect the pharmacodynamics of aspirin. 26 Our approach to examine medication use as a time-varying covariate is a distinct advantage over analyses that only examined baseline medication use. In our approach, participants could migrate to other risk sets during the course Multiple concurrent usages are counted in each of the respective categories such that groups are not mutually exclusive. NSAID indicates nonsteroidal antiinflammatory drug.
of follow-up. For example, a given participant could first contribute time in the risk set of regular NSAID use, then contribute time in the risk set of no NSAID use, and then possibly contribute time again in the risk set of regular NSAID use. In fact, we observed significant migration to and from NSAID use and also between types of NSAIDs, which supports our time-varying methodology. Likewise, we also included other important medications, such as aspirin, as a time-varying covariate. At the time women were enrolled in WHI (ie, between 1983 and 1988), selective cox-2 inhibitors were not in clinical use; however, over time participants reported the use of both celecoxib and rofecoxib. Because we performed a time-varying analysis, these women were still able to contribute person-time data to the model. Both of these agents were associated with the same magnitude of hazard for increased cardiovascular events. This is consistent with other reports that have documented a class effect among the selective cox-2 inhibitors. 27 Counter to previous reports, 2,10,28-32 naproxen was associated with increased risk, whereas ibuprofen was not. This was consistent with our a priori study hypothesis. This finding is also consistent with a clinical trial designed to prevent Alzheimer dementia with the use of NSAIDs. This study was terminated early because of possibly increased risk for adverse cardiovascular events among naproxen versus placebo users. 33 Other agents within group 2 were also directionally associated with risk increase; however, only ketorolac reached statistical significance. Associations within group 3 ranged from statistically significant decreased risk (eg, oxaprozin) to increased risk (eg, ketoprofen and flurbiprofen). However, these were based on few events, and these findings have to be interpreted with caution in this observational study.
A recent meta-analysis of randomized trials documented an increased hazard for major vascular events with high-dose diclofenac and coxib medications but not with high-dose Individual agents are mutually exclusive exposure groups. Concurrent use of ≥1 agent is considered as a separate group. P-value < 0.05 significant. CI indicates confidence interval; HR, hazard ratio; and NSAID, nonsteroidal anti-inflammatory drug.
*Covariates included in the final model of the primary outcome are (P value): age (<0.001), ethnicity (<0.001), education (0.022), income (<0.001), region of residence within the United States (0.045), body mass index (0.0002), systolic blood pressure (<0.001), physical activity (<0.001), history of rheumatoid arthritis (<0.001), hypertension (<0.001), high cholesterol (0.0009), diabetes mellitus (<0.001), myocardial infarction (<0.001), stroke or transient ischemic attack (<0.001), congestive heart failure (<0.001), coronary artery bypass grafting or percutaneous coronary intervention (<0.001), peripheral arterial disease (<0.001), smoking status (<0.001), menopausal hormone use (0.001), statin use (time-varying covariate, 0.025), acetaminophen use (time-varying, 0.015), and aspirin use (time-varying, 0.025). In addition, we included an interaction term between aspirin and menopausal hormones (0.005) because of improved model fit as indicated by Akaike information criterion.
naproxen. 34 The reason for the differences in these study findings is not known. One potential explanation why naproxen was not observed to be associated with increased hazard for cardiovascular events in the meta-analysis is that high-dose naproxen (eg, 500 mg twice daily) is able to produce an aspirin-like effect through near-complete inhibition of cox-1. 35 Although we did not have data on medication dosage in the current analysis, naproxen use in WHI was likely closer to 220 mg twice daily. With a lower dosage (and less frequent use) of naproxen, inhibition of cox-2 when compared with cox-1 might become more pronounced and allow for more platelet aggregation to occur. 7, 35 There may also be variability in the hazardous effects of these medications according to the duration of use (median follow-up, >10 years in WHI) and sex, which was exclusively women in WHI.
We recognize that elevations in blood pressure could be caused by regular NSAID use and thus could be viewed as a biological intermediate in the causal pathway of NSAID usage to the primary event. To investigate potential overcontrol for this risk factor, we estimated models with and without history of hypertension and systolic blood pressure, and the resulting differences on the NSAID-related estimates were small. Accordingly, we decided to keep these variables in the overall model. Clearly, high blood pressure can have causes other than NSAID usage, and harmful effects of NSAIDs could be influenced by blood pressure-independent pathways (eg, platelet aggregation).
Limitations
The classification of NSAIDs according to relative inhibition of cox-2 compared with cox-1 was motivated by an exvivo study performed in healthy volunteers. 22 It is unknown whether similar findings would be observed among individuals with established atherosclerosis; however, this constituted a minority of the WHI cohort.
We did not have information on when aspirin or nonaspirin NSAIDs were taken in relation to each other. This could be important because ibuprofen has been shown to block the antiplatelet effect of aspirin when taken before this agent. 26 We did not have information of dosage of NSAIDs; therefore, our findings apply to NSAID use in a general sense. Women who participated in the different components of WHI may systematically differ in their respective risk for cardiovascular events because of different exclusion criteria in the WHI clinical trials. However, we allowed for that possibility by stratifying our Cox regression on WHI trial membership. Our statistical model only required that all women share the same relative effect of a covariate (including NSAID usage) across strata, with possibly different baseline hazard functions for cardiovascular events.
The available medication information is detailed, but sparsely collected, especially for the women in the observational component of WHI who were only sampled at baseline and year 3. We implicitly assumed that a woman's medication did not change between the actually recorded medication updates. This assumption was increasingly questionable the less frequently the medication information was updated. This motivated the sensitivity analyses to restrict to randomized trial participants with more frequent medication history updates and censor all women 3 years after their last medication update. We found that NSAID medication was not stable for a long period of time with migration to nonuse and to other types of NSAIDs. This finding supports our assertion that NSAID use was best modeled as a time-varying covariate.
We did not have outcome information on acute renal failure, renal function, or gastrointestinal hemorrhage, which are all possible mechanisms by which NSAIDs could exert harmful effects. Congestive heart failure was recorded; however, this was not as rigorously adjudicated as other WHI outcomes. Selection bias was mitigated by including a missing group in categorical covariates whenever feasible that allowed us to keep women with partially missing data in this study, a strategy that allowed us to use 160 801 of the 161 808 WHI enrollees (99.4%). This, of course, does not control for any bias that might be inherent in the group of women enrolled in WHI.
Conclusions
The regular use of selective cox-2 inhibitors and nonselective NSAIDs with cox-2>cox-1 inhibition showed a modestly increased hazard for cardiovascular events. Concomitant Figure 2 . Adjusted hazard ratios for the primary outcome (cardiovascular mortality, nonfatal myocardial infarction, or nonfatal stroke) and secondary outcomes for regular nonsteroidal anti-inflammatory drug (NSAID) use versus no NSAID use. Group 1=cox-2 selective agents, group 2=nonselective agents with cox-2>cox-1 inhibition, and group 3=nonselective agents with cox-1>cox-2 inhibition. aspirin attenuated the increased hazard for cardiovascular events associated with selective cox-2 inhibitors but not nonselective NSAIDs with cox-2>cox-1 inhibition. We did not identify greater cardiovascular risk for medications with more cox-1>cox-2 inhibition. As such, these agents may be safer from a cardiovascular perspective for long-term use among postmenopausal women.
